JP6878395B2 - 過リン酸化タウに特異的な抗体およびその使用方法 - Google Patents

過リン酸化タウに特異的な抗体およびその使用方法 Download PDF

Info

Publication number
JP6878395B2
JP6878395B2 JP2018501228A JP2018501228A JP6878395B2 JP 6878395 B2 JP6878395 B2 JP 6878395B2 JP 2018501228 A JP2018501228 A JP 2018501228A JP 2018501228 A JP2018501228 A JP 2018501228A JP 6878395 B2 JP6878395 B2 JP 6878395B2
Authority
JP
Japan
Prior art keywords
tau
antibody
amino acid
seq
epitope
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2018501228A
Other languages
English (en)
Japanese (ja)
Other versions
JP2018531580A (ja
JP2018531580A5 (ru
Inventor
ピーダスン，ヤン，トアライフ
ピーダスン，ラース，ウスタゴー
デクセル，ユストゥス，クラウス，アルフレッド
アスニ，アヨデジ アブドゥル−ラシード
アスニ，アヨデジ アブドゥル−ラシード
ローゼンクヴィスト，ニーナ
Original Assignee
ハー・ルンドベック・アクチエゼルスカベット
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB1512211.2A external-priority patent/GB201512211D0/en
Priority claimed from GBGB1518375.9A external-priority patent/GB201518375D0/en
Application filed by ハー・ルンドベック・アクチエゼルスカベット filed Critical ハー・ルンドベック・アクチエゼルスカベット
Publication of JP2018531580A publication Critical patent/JP2018531580A/ja
Publication of JP2018531580A5 publication Critical patent/JP2018531580A5/ja
Application granted granted Critical
Publication of JP6878395B2 publication Critical patent/JP6878395B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Images

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00—Preparations for testing in vivo
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16—Anti-Parkinson drugs
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/34—Identification of a linear epitope shorter than 20 amino acid residues or of a conformational epitope defined by amino acid residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4709—Amyloid plaque core protein
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2814—Dementia; Cognitive disorders
    • G01N2800/2821—Alzheimer

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biomedical Technology (AREA)
  • Organic Chemistry (AREA)
  • Immunology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Molecular Biology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biochemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Microbiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Cell Biology (AREA)
  • Biotechnology (AREA)
  • Mycology (AREA)
  • Psychology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Cardiology (AREA)
JP2018501228A 2015-07-13 2016-07-12 過リン酸化タウに特異的な抗体およびその使用方法 Active JP6878395B2 (ja)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
GB1512211.2 2015-07-13
GBGB1512211.2A GB201512211D0 (en) 2015-07-13 2015-07-13 Agents, uses and methods
GBGB1518375.9A GB201518375D0 (en) 2015-10-16 2015-10-16 Agents,uses and methods
GB1518375.9 2015-10-16
PCT/EP2016/066470 WO2017009308A2 (en) 2015-07-13 2016-07-12 Antibodies specific for hyperphosphorylated tau and methods of use thereof

Publications (3)

Publication Number Publication Date
JP2018531580A JP2018531580A (ja) 2018-11-01
JP2018531580A5 JP2018531580A5 (ru) 2019-08-15
JP6878395B2 true JP6878395B2 (ja) 2021-05-26

Family

ID=56557664

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2018501228A Active JP6878395B2 (ja) 2015-07-13 2016-07-12 過リン酸化タウに特異的な抗体およびその使用方法

Country Status (32)

Country Link
US (4) US10196439B2 (ru)
EP (1) EP3322442A2 (ru)
JP (1) JP6878395B2 (ru)
KR (1) KR20180030047A (ru)
CN (1) CN107847595B (ru)
AU (1) AU2016292892B2 (ru)
BR (1) BR112018000769A2 (ru)
CA (1) CA2990555A1 (ru)
CL (1) CL2018000096A1 (ru)
CO (1) CO2017013318A2 (ru)
CR (1) CR20180026A (ru)
DO (1) DOP2018000012A (ru)
EA (1) EA038703B1 (ru)
EC (1) ECSP18002644A (ru)
GE (1) GEP20227369B (ru)
HK (1) HK1254357A1 (ru)
IL (1) IL256791B (ru)
JO (1) JO3711B1 (ru)
MA (1) MA42446A (ru)
MX (1) MX2018000505A (ru)
NI (1) NI201800005A (ru)
NZ (1) NZ738595A (ru)
PE (1) PE20180607A1 (ru)
PH (1) PH12018500062A1 (ru)
RU (1) RU2727911C2 (ru)
SG (1) SG10202101343RA (ru)
SV (1) SV2018005611A (ru)
TN (1) TN2017000541A1 (ru)
TW (1) TWI741987B (ru)
UA (1) UA123862C2 (ru)
WO (1) WO2017009308A2 (ru)
ZA (1) ZA201800070B (ru)

Cited By (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506954A (ja) * 2017-01-04 2020-03-05 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体

Families Citing this family (36)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
JO3627B1 (ar) 2015-04-30 2020-08-27 H Lundbeck As إيميدازو بيرازينونات على هيئة مثبطات pde1
RU2732122C2 (ru) 2015-06-05 2020-09-11 Дженентек, Инк. Антитела против тау-белка и способы их применения
TN2017000543A1 (en) 2015-07-06 2019-04-12 Ucb Biopharma Sprl Tau-binding antibodies
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
WO2017191559A1 (en) 2016-05-02 2017-11-09 Prothena Biosciences Limited Tau immunotherapy
CU24537B1 (es) 2016-05-02 2021-07-02 Prothena Biosciences Ltd Anticuerpos monoclonales que compiten por unirse a tau humano con el anticuerpo 3d6
US10034861B2 (en) 2016-07-04 2018-07-31 H. Lundbeck A/S 1H-pyrazolo[4,3-b]pyridines as PDE1 inhibitors
MY197836A (en) * 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
WO2018035137A1 (en) * 2016-08-15 2018-02-22 The Board Of Regents Of The University Of Texas System Volume control device for manually operated resuscitator and ventilation apparatus and method of use
SI3532064T1 (sl) 2016-10-28 2020-10-30 H. Lundbeck A/S Kombinirana zdravljenja, ki obsegajo imidazopirazinone za zdravljenje psihiatričnih in/ali kognitivnih motenj
JP2020500841A (ja) 2016-10-28 2020-01-16 ハー・ルンドベック・アクチエゼルスカベット イミダゾピラジノンの投与を含む併用療法
MX2019006334A (es) 2016-12-07 2019-08-01 Genentech Inc Anticuerpos antitau y métodos de uso.
CA3045294A1 (en) 2016-12-07 2018-06-14 Genentech, Inc. Anti-tau antibodies and methods of use
MX2019009817A (es) 2017-02-17 2019-11-21 Denali Therapeutics Inc Anticuerpos anti-tau y metodos de uso de los mismos.
JP2018139530A (ja) 2017-02-27 2018-09-13 帝人ファーマ株式会社 認知症治療又は予防のためのヒト化抗体及びその製造方法、並びにそれを用いた認知症治療剤又は予防剤
EA039569B1 (ru) * 2017-03-14 2022-02-11 Х. Лундбекк А/С Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения
IL270375B1 (en) 2017-05-02 2024-08-01 Prothena Biosciences Ltd Antibodies that recognize tau
WO2019077500A1 (en) 2017-10-16 2019-04-25 Eisai R&D Management Co., Ltd. ANTI-WATER ANTIBODIES AND USES THEREOF
AR113926A1 (es) 2017-12-14 2020-07-01 H Lundbeck As Derivados de 1h-pirazolo[4,3-b]piridinas
US11634416B2 (en) 2017-12-14 2023-04-25 H. Lundbeck A/S Combination treatments comprising administration of 1H-pyrazolo[4,3-b]pyridines
CN117447475A (zh) 2017-12-20 2024-01-26 H.隆德贝克有限公司 作为PDE1抑制剂的吡唑并[4,3-b]吡啶和咪唑并[1,5-a]嘧啶
WO2019149798A1 (en) * 2018-02-01 2019-08-08 Janssen Vaccines & Prevention B.V. Binding molecules that specifically bind to tau
CU20210073A7 (es) 2019-03-03 2022-04-07 Prothena Biosciences Ltd Anticuerpos que se unen dentro de la región de unión a microtúbulos de tau definida por cdrs
WO2020193500A1 (en) 2019-03-28 2020-10-01 H. Lundbeck A/S Use of a ps396 assay to diagnose tauophaties
WO2021211753A1 (en) 2020-04-15 2021-10-21 Voyager Therapeutics, Inc. Tau binding compounds
IL299292A (en) 2020-06-25 2023-02-01 Merck Sharp & Dohme Llc High-affinity antibodies to tau phosphorylated at serine 413
US11965024B2 (en) 2020-09-11 2024-04-23 Janssen Biotech, Inc. Methods and compositions for modulating beta chain mediated immunity
KR20230084507A (ko) * 2020-09-11 2023-06-13 얀센 바이오테크 인코포레이티드 다중-특이적 면역 표적화 분자 및 그의 용도
WO2022104136A2 (en) * 2020-11-12 2022-05-19 Children's Medical Center Corporation Methods and compositions for tauopathy diagnosis and treatment
TW202239765A (zh) 2020-12-16 2022-10-16 美商航海家醫療公司 Tau結合化合物
CN113702647B (zh) * 2021-08-31 2024-03-15 普十生物科技(北京)有限公司 人生长分化因子15即时检测试剂盒、其制备方法及其应用
WO2023092004A1 (en) 2021-11-17 2023-05-25 Voyager Therapeutics, Inc. Compositions and methods for the treatment of tau-related disorders
WO2023250388A1 (en) 2022-06-22 2023-12-28 Voyager Therapeutics, Inc. Tau binding compounds
WO2024059739A1 (en) 2022-09-15 2024-03-21 Voyager Therapeutics, Inc. Tau binding compounds
WO2024067401A1 (zh) * 2022-09-26 2024-04-04 中美华世通生物医药科技(武汉)股份有限公司 包含Fc-高级脂肪酸链的超长效平台

Family Cites Families (69)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS5896026A (ja) 1981-10-30 1983-06-07 Nippon Chemiphar Co Ltd 新規ウロキナ−ゼ誘導体およびその製造法ならびにそれを含有する血栓溶解剤
EP0098110B1 (en) 1982-06-24 1989-10-18 NIHON CHEMICAL RESEARCH KABUSHIKI KAISHA also known as JAPAN CHEMICAL RESEARCH CO., LTD Long-acting composition
US4766106A (en) 1985-06-26 1988-08-23 Cetus Corporation Solubilization of proteins for pharmaceutical compositions using polymer conjugation
US5101827A (en) 1985-07-05 1992-04-07 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5776093A (en) 1985-07-05 1998-07-07 Immunomedics, Inc. Method for imaging and treating organs and tissues
US4735210A (en) 1985-07-05 1988-04-05 Immunomedics, Inc. Lymphographic and organ imaging method and kit
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US4861581A (en) 1986-12-05 1989-08-29 Cancer Biologics, Inc. Detection of necrotic malignant tissue and associated therapy
US5750172A (en) 1987-06-23 1998-05-12 Pharming B.V. Transgenic non human mammal milk
US5648471A (en) 1987-12-03 1997-07-15 Centocor, Inc. One vial method for labeling antibodies with Technetium-99m
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5703055A (en) 1989-03-21 1997-12-30 Wisconsin Alumni Research Foundation Generation of antibodies through lipid mediated DNA delivery
ATE172879T1 (de) 1989-08-09 1998-11-15 Rhomed Inc Direkte radioetikettierung von antikörpern und sonstigen proteinen mittels technetium oder rhenium
US5633076A (en) 1989-12-01 1997-05-27 Pharming Bv Method of producing a transgenic bovine or transgenic bovine embryo
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
AU2235992A (en) 1991-06-14 1993-01-12 Genpharm International, Inc. Transgenic immunodeficient non-human animals
WO1992022653A1 (en) 1991-06-14 1992-12-23 Genentech, Inc. Method for making humanized antibodies
WO1993001227A1 (en) 1991-07-08 1993-01-21 University Of Massachusetts At Amherst Thermotropic liquid crystal segmented block copolymer
JPH07507044A (ja) 1991-12-06 1995-08-03 マックス−プランク−ゲゼルシャフト　ツール　フェルデルング　デル　ヴィッセンシャフテン　エー．ヴェー． アルツハイマー病の診断および治療用の新規な手段
JPH07503132A (ja) 1991-12-17 1995-04-06 ジェンファーム　インターナショナル，インコーポレイティド 異種抗体を産生することができるトランスジェニック非ヒト動物
JP3801196B2 (ja) 1993-03-09 2006-07-26 ジェンザイム・コーポレイション 乳からの対象化合物の単離
JPH08509612A (ja) 1993-04-26 1996-10-15 ジェンファーム インターナショナル インコーポレイテッド 異種抗体を産生することができるトランスジェニック非ヒト動物
US5827690A (en) 1993-12-20 1998-10-27 Genzyme Transgenics Corporatiion Transgenic production of antibodies in milk
US6077835A (en) 1994-03-23 2000-06-20 Case Western Reserve University Delivery of compacted nucleic acid to cells
KR970029803A (ko) 1995-11-03 1997-06-26 김광호 반도체 메모리장치의 프리차지 회로
CA2361421A1 (en) 1999-02-03 2000-08-10 Biosante Pharmaceuticals, Inc. Therapeutic calcium phosphate particles and methods of manufacture and use
US6281005B1 (en) 1999-05-14 2001-08-28 Copernicus Therapeutics, Inc. Automated nucleic acid compaction device
DE60037896D1 (de) 1999-07-29 2008-03-13 Medarex Inc Menschliche antikörper gegen her2/neu
EP3214175A1 (en) 1999-08-24 2017-09-06 E. R. Squibb & Sons, L.L.C. Human ctla-4 antibodies and their uses
US20030162230A1 (en) * 2000-09-27 2003-08-28 Reagan Kevin J. Method for quantifying phosphokinase activity on proteins
PT1354034E (pt) 2000-11-30 2008-02-28 Medarex Inc Roedores transgénicos transcromossómicos para produção de anticorpos humanos
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US8003108B2 (en) * 2005-05-03 2011-08-23 Amgen Inc. Sclerostin epitopes
JP2009506302A (ja) 2005-08-04 2009-02-12 イェシバ・ユニバーシティ Ａｂｌによるタウのリン酸化
WO2007059782A1 (en) 2005-11-28 2007-05-31 Genmab A/S Recombinant monovalent antibodies and methods for production thereof
EP3255144A1 (en) 2007-08-10 2017-12-13 E. R. Squibb & Sons, L.L.C. Recombineering construct for preparing transgenic mice capable of producing human immunoglobulin
EP2527369A3 (en) 2007-09-13 2012-12-19 University Of Zurich Prorektorat Forschung Monoclonal amyloid beta (abeta)-specific antibody and uses thereof
US8609097B2 (en) 2009-06-10 2013-12-17 Hoffmann-La Roche Inc. Use of an anti-Tau pS422 antibody for the treatment of brain diseases
WO2010144711A2 (en) 2009-06-10 2010-12-16 New York University Immunological targeting of pathological tau proteins
WO2011052519A1 (ja) 2009-10-26 2011-05-05 大塚製薬株式会社 ベンズアゼピン化合物
HUE027649T2 (en) * 2010-10-07 2016-10-28 Ac Immune Sa Phosphonus recognition antibodies
JP2014503178A (ja) 2010-10-11 2014-02-13 バイオジェン アイデック インターナショナル ニューロサイエンス ゲーエムベーハー ヒト抗タウ抗体
PT2758433T (pt) * 2011-09-19 2018-01-19 Axon Neuroscience Se Terapia à base de proteínas e diagnóstico de patologia mediada por tau na doença de alzheimer
CA2850686C (en) 2011-10-07 2020-09-08 Ac Immune S.A. Phosphospecific antibodies recognising tau
MX356800B (es) 2012-04-05 2018-06-13 Ac Immune Sa Anticuerpo tau humanizado.
SG11201408626YA (en) 2012-07-03 2015-03-30 Univ Washington Antibodies to tau
JP6290212B2 (ja) 2012-08-16 2018-03-07 アイピエリアン，インコーポレイティド タウオパチーの処置方法
EP2970453B1 (en) 2013-03-13 2019-12-04 Prothena Biosciences Limited Tau immunotherapy
US20160068818A1 (en) * 2013-04-16 2016-03-10 Glykos Finland Oy A method for generating induced pluripotent stem cells
CN107073297B (zh) 2014-07-08 2021-09-14 纽约大学 Tau显像配体和其在Tau蛋白病的诊断和治疗中的用途
JO3711B1 (ar) 2015-07-13 2021-01-31 H Lundbeck As أجسام مضادة محددة لبروتين تاو وطرق استعمالها
MY197836A (en) 2016-07-12 2023-07-20 H Lundbeck As Antibodies specific for hyperphosphorylated tau and methods of use thereof
US10364286B2 (en) * 2016-12-22 2019-07-30 H. Lundbeck A/S Monoclonal anti-alpha-synuclein antibodies for preventing tau aggregation
EP3565836A1 (en) 2017-01-04 2019-11-13 H. Lundbeck A/S Antibodies specific for hyperphosphorylated tau for the treatment of ocular diseases
US10934438B2 (en) 2017-04-27 2021-03-02 Axalta Coating Systems Ip Co., Llc Coatings and methods for using and producing the same

Cited By (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2020506954A (ja) * 2017-01-04 2020-03-05 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体
JP7217710B2 (ja) 2017-01-04 2023-02-03 ハー・ルンドベック・アクチエゼルスカベット 眼疾患の治療のための過リン酸化タウに特異的な抗体

Also Published As

Publication number Publication date
US20190177401A1 (en) 2019-06-13
ZA201800070B (en) 2019-04-24
JP2018531580A (ja) 2018-11-01
CO2017013318A2 (es) 2018-05-21
US10196439B2 (en) 2019-02-05
BR112018000769A2 (pt) 2018-09-25
RU2727911C2 (ru) 2020-07-24
US10934348B2 (en) 2021-03-02
IL256791A (en) 2018-03-29
MX2018000505A (es) 2018-04-30
TWI741987B (zh) 2021-10-11
WO2017009308A2 (en) 2017-01-19
SV2018005611A (es) 2018-02-23
US20170015738A1 (en) 2017-01-19
CL2018000096A1 (es) 2018-07-06
NI201800005A (es) 2018-10-19
US10562962B2 (en) 2020-02-18
CR20180026A (es) 2018-03-08
MA42446A (fr) 2018-05-23
US20200190178A1 (en) 2020-06-18
EP3322442A2 (en) 2018-05-23
CN107847595B (zh) 2021-09-24
HK1254357A1 (zh) 2019-07-19
NZ738595A (en) 2022-07-01
IL256791B (en) 2022-09-01
CA2990555A1 (en) 2017-01-19
ECSP18002644A (es) 2018-03-31
WO2017009308A3 (en) 2017-04-06
PE20180607A1 (es) 2018-04-09
EA038703B1 (ru) 2021-10-07
DOP2018000012A (es) 2018-02-28
UA123862C2 (uk) 2021-06-16
JO3711B1 (ar) 2021-01-31
US20210206843A1 (en) 2021-07-08
KR20180030047A (ko) 2018-03-21
TN2017000541A1 (en) 2019-04-12
CN107847595A (zh) 2018-03-27
RU2018100822A (ru) 2019-08-13
RU2018100822A3 (ru) 2019-12-26
AU2016292892B2 (en) 2021-11-18
US11739140B2 (en) 2023-08-29
PH12018500062A1 (en) 2018-07-09
TW201716436A (zh) 2017-05-16
SG10202101343RA (en) 2021-03-30
AU2016292892A1 (en) 2018-01-18
GEP20227369B (en) 2022-04-11
EA201890039A1 (ru) 2018-08-31

Similar Documents

Publication Publication Date Title
JP6878395B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
JP7244600B2 (ja) 過リン酸化タウに特異的な抗体およびその使用方法
JP7217710B2 (ja) 眼疾患の治療のための過リン酸化タウに特異的な抗体
OA18779A (en) Antibodies Specific for Hyperphosphorylated Tau and Methods of Use Thereof.
EA039569B1 (ru) Антитела, специфичные к гиперфосфорилированному тау-белку, и способы их применения

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20190708

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20190708

A977 Report on retrieval

Free format text: JAPANESE INTERMEDIATE CODE: A971007

Effective date: 20200525

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20200616

A601 Written request for extension of time

Free format text: JAPANESE INTERMEDIATE CODE: A601

Effective date: 20200819

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20201209

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20210420

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20210428

R150 Certificate of patent or registration of utility model

Ref document number: 6878395

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250